For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Vyndamax and Attruby represents a significant advancement . These novel therapies stabilize the transthyretin protein, halting its damaging build-up and alleviating the burden of the illness. People are now reporting improvements i